Copper aspirinate Copper aspirinate Copper(II) aspirinate is an aspirin chelate of copper(II) cations (Cu). It is used to treat rheumatoid arthritis. Copper aspirinate can be prepared by several methods. In one route of preparation, an excess of acetylsalicylic acid is dissolved in aqueous sodium carbonate. Sodium hydroxide is not suitable for this purpose, because it will hydrolyse acetylsalicylic acid ("ASA") into salicylic acid and sodium acetate. The resulting solution is then filtered to remove any undissolved acetylsalicylic acid and is mixed with a solution containing Cu cations (copper(II) sulfate is suitable), precipitating bright blue crystals of copper aspirinate immediately. The crystals can
Obeticholic acid synthesis, have been found in this condition. FGF19 is potently stimulated by bile acids and especially by OCA. A proof of concept study of OCA (25 mg/d) has shown clinical and biochemical benefit. On February 1, 2018, the FDA updated label warnings for Obeticholic acid to better explain recommended dosing. According to the agency, misunderstanding led some health care professionals to improperly dose the drug on a daily basis rather than weekly, which can increase the risk of liver damage. Obeticholic acid Obeticholic acid (abbreviated to OCA, trade name Ocaliva), is a semi-synthetic bile acid analogue which has the chemical